Technology for drug products addressing medical needs
Silicon Nanoparticles for Drug Delivery
Nacamed's technology is built upon a unique process for synthesizing tailor-made porous silicon nanoparticles. Our bottom-up chemical vapor deposition (CVD) method ensures scalable and precise production of particles. These nanoparticles have a wide range of therapeutic applications and offer key advantages:
Controlled Drug Release – Tailored particle properties optimize the release profile of active substances.
Enhanced Bioavailability – Particularly beneficial for drugs with poor solubility.
Efficient Hydrogen Therapy – Safe delivery of high-dose hydrogen delivery.
Safe and Biocompatible – No extreme chemicals required, making the process both efficient and environmentally friendly.
Over the past two decades, numerous scientific studies have highlighted the potential of silicon nanoparticles in medicine. However, the transition from research to commercial pharmaceutical products has been hindered by the commercial production processes for useful medical nanoparticles. Nacamed addresses this gap by combining state-of-the-art research with our unique, precision-engineered nanoparticle synthesis process, enabling the development of clinically viable nanomedicine products.
Unique Silicon Nanoparticle Matrix
Potential medical applications of silicon nanoparticles described in the prior art include silica-based particles (SiO2) and particles based on non-oxidized silicon (Si).
The Nacamed nanoparticles are stable clusters of tiny silicon (Si) particles prepared by a proprietary production process via chemical vapor decomposition (CVD) from silane gas (SiH4).
Our CVD process have the following advantages:
Scalable (currently a semi-commercial process)
One step production process with no need for HF (Hydrofluoric acid)
Yield tailor-made nanoparticles (from appr. 100 nm to several micrometer size)
Flexible production (e.g. porosity is adjustable in nm size)
TECHNOLOGY BENEFITS
The Nacamed drug delivery technology has multiple competitive advantages over other alternative delivery technologies
SAFETY
Silicon is a natural element in the human body.
Preliminary studies indicate that the Nacamed particles are safe.
The Nacamed particles have a simple metabolism – in vivo degradation by oxidation generating silicic acid/silica and hydrogen.
Silica particles are already approved and widely used as food additives and in tablet compositions.
VERSATILITY
Suitable for small drug molecules (molecular weight below 1000 D) and larger drug subtances including biomolecules.
Suitable for drug substances with variable solubility properties; specially useful for poorly water soluble compounds
Suitable administration routes include both enteral and parenteral administration with focus on oral administration (tablets and capsules) and subcutaneous administration of suspensions.
SUSTAINABILITY
Silicon is the second most abundant chemical element on earth.
Improved oral bioavailability reduces the administered drug dose and thereby the drug pollution of nature. This is an especially important for toxic drugs including antibiotics and drugs for cancer treatment.
Hydrogen gas is harmless to both humans and nature. Compared to other well-known drug substances used for the same indications, hydrogen has little to no pollution footprint.
COMMERCIAL BENEFITS
Product development based on existing products and/or existing drug substances reduces the development cost, and technical and commercial risks.
New products will have their own protected trade names.
New or improved IP coverage including patent coverage will secure reduce generic substitution.
The new products will be prized based om their clinical performance.
Nacamed is excited to explore new commercial and academic collaborations; principally within in vitro and in vivo studies in established models around potential new drug substances and super generic drug formulations
Our partners and colloborators
Nacamed is always looking for new academic collaborations; principally within in vitro and in vivo studies in established models.
Nacamed is also interested in commercial collaborations with other pharmaceutical companies including potential new drug candidates and super generic drug products.
